'We want to look at the infections that we get - and we will get breakthrough infections. The vaccine, Gray said, proved effective against the Beta and Delta variants, which are both prevalent in South Africa.Īn analysis of the data, which was done in three ways, looked at the effectiveness of the vaccine. The trial reached over 470 000 healthcare workers in over 120 sites across the country. The study commenced on 17 February 2021 and concluded on. This was on Friday revealed by Professor Glenda Gray, the CEO of the Medical Research Council and co-lead investigator, during the Health Department’s weekly briefing.
The results of the Sisonke programme study have revealed that the Johnson & Johnson vaccine has provided effective protection against serious illness and death from COVID-19 infection.
